SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
J. Randolph Hecht
Research Funding - Amgen
Allen Lee Cohn
No relevant relationships to disclose
Shaker R. Dakhil
No relevant relationships to disclose
Mansoor N. Saleh
No relevant relationships to disclose
Bilal Piperdi
Consultant or Advisory Role - Amgen
Vivian Jean M. Cline-Burkhardt
No relevant relationships to disclose
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen